Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
6.81
-0.01 (-0.15%)
Feb 21, 2025, 4:00 PM EST - Market closed
Astria Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Astria Therapeutics stock have an average target of 25.67, with a low estimate of 16 and a high estimate of 35. The average target predicts an increase of 276.95% from the current stock price of 6.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Astria Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Initiates $26 | Buy | Initiates | $26 | +281.79% | Jan 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +134.95% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +134.95% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +134.95% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.73
from -2.42
EPS Next Year
-1.87
from -1.73
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 5.3M | |||
| Avg | n/a | n/a | 1.0M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.53 | -1.69 | -1.72 | |||
| Avg | -1.73 | -1.87 | -1.96 | |||
| Low | -1.91 | -2.08 | -2.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.